Research Article
The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems
Table 4
Results of univariate analysis of the factors that influence the OS.
| | Characteristics | (%) | Median OS (months) | value |
| | Sex | | | | | Male | 23 (69.7) | 37 | 0.721 | | Female | 10 (30.3) | 22 |
| | Age | | | | | <60 | 15 (45.5) | 31 | 0.915 | | ≥60 | 18 (54.5) | 33 |
| | Type | | | | | IgG | 21 (63.6) | NR | 0.243 | | IgA | 1 (3.0) | 33 | | Light chain | 8 (24.2) | 7 | | Others | 3 (9.1) | 38 |
| | Bone marrow | | | | | Deauville score ≥4 | 10 (30.3) | 7 | 0.013 | | Deauville score <4 | 23 (69.7) | 38 |
| | Paramedullary disease | | | | | + | 17 (51.5) | 33 | 0.513 | | − | 16 (48.5) | 37 |
| | Extramedullary disease | | | | | + | 16 (48.5) | 16 | 0.015 | | − | 17 (51.5) | NR | | Creatinine | | | | | <2 mg/dl | 22 (66.7) | 37 | 0.064 | | ≥2 mg/dl | 11 (33.3) | 16 |
| | Subgroup of DS Plus | | | | | A | 12 (36.4) | NR | 0.012 | | B | 21 (63.6) | 16 |
| | Treatment | | | | | None | 11 (33.3) | 31 | 0.146 | | Chemotherapy | 7 (21.2) | 37 | | Chemotherapy + IMIDs | 9 (27.3) | NR | | Chemotherapy + BMT | 4 (12.1) | 27 | | Others | 2 (6.1) | 7 |
|
|
NR: not reached; BMT: bone marrow transplant.
|
